GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Cyclically Adjusted FCF per Share

US Stem Cell (US Stem Cell) Cyclically Adjusted FCF per Share : $0.00 (As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

US Stem Cell's adjusted free cash flow per share for the three months ended in Dec. 2022 was $0.000. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-06), US Stem Cell's current stock price is $0.0001. US Stem Cell's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2022 was $0.00. US Stem Cell's Cyclically Adjusted Price-to-FCF of today is .


US Stem Cell Cyclically Adjusted FCF per Share Historical Data

The historical data trend for US Stem Cell's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Cyclically Adjusted FCF per Share Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -15.52 - - -

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of US Stem Cell's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, US Stem Cell's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Stem Cell's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where US Stem Cell's Cyclically Adjusted Price-to-FCF falls into.



US Stem Cell Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, US Stem Cell's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2022 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-0/125.2218*125.2218
=0.000

Current CPI (Dec. 2022) = 125.2218.

US Stem Cell Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201303 -2.951 98.209 -3.763
201306 -2.518 98.518 -3.201
201309 -1.927 98.790 -2.443
201312 -0.972 98.326 -1.238
201403 -0.517 99.695 -0.649
201406 -0.528 100.560 -0.657
201409 -0.462 100.428 -0.576
201412 -0.643 99.070 -0.813
201503 -0.614 99.621 -0.772
201506 -0.280 100.684 -0.348
201509 -0.171 100.392 -0.213
201512 -0.032 99.792 -0.040
201603 -0.030 100.470 -0.037
201606 -0.019 101.688 -0.023
201609 0.003 101.861 0.004
201612 0.002 101.863 0.002
201703 0.001 102.862 0.001
201706 0.002 103.349 0.002
201709 0.001 104.136 0.001
201712 0.001 104.011 0.001
201803 0.002 105.290 0.002
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 -0.001 107.251 -0.001
201906 0.000 108.070 0.000
201909 -0.001 108.329 -0.001
201912 -0.001 108.420 -0.001
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.000 109.897 0.000
202103 -0.001 111.754 -0.001
202106 -0.001 114.631 -0.001
202109 0.000 115.734 0.000
202112 0.000 117.630 0.000
202203 0.000 121.301 0.000
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


US Stem Cell  (OTCPK:USRM) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


US Stem Cell Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


US Stem Cell (US Stem Cell) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines

From GuruFocus

Corrected: USRM Posts Earnings for Second Quarter 2019

By PRNewswire PRNewswire 08-10-2019

USRM Posts Increase in Revenue and Profit Margin for 2018

By PRNewswire PRNewswire 03-14-2019

USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

By PRNewswire PRNewswire 11-08-2018

Court Reports Favorable Judgment in California Stem Cell Case

By ACCESSWIRE ACCESSWIRE 09-01-2022

USRM Posts Financial Results for First Quarter 2019

By PRNewswire PRNewswire 05-08-2019

Mark Borman Appointed Chairman of the Board of USRM

By ACCESSWIRE ACCESSWIRE 03-09-2022

USRM Oral Argument in Appeal from FDA Enforcement Action

By ACCESSWIRE ACCESSWIRE 01-19-2021